Glenmark Receives Russian Marketing Approval For Ryaltris Nasal Spray

Glenmark Receives Russian Marketing Approval For Ryaltris Nasal Spray

By, Admin 23 February 2021

Glenmark Pharmaceuticals Ltd. (Glenmark), A Research-Led Global Integrated Pharmaceutical Company, Announced That Its Swiss Subsidiary, Glenmark Specialty S.A., Received Marketing Approval From The Ministry Of Health Of The Russian Federation For Its Innovative Ryaltris Nasal Spray, A Novel Fixed-Dose Combination Nasal Spray.This Paves The Way For Commercialization Of Ryaltris In Russia Which Is Expected To Be Made Available To Patients In The Country In Q1 Fy 2021-22.Ryaltris (Olopatadine Hydrochloride 665 Mcg And Mometasone Furoate 25 Mcg), Is Indicated For Symptomatic Treatment Of Seasonal And Perennial Allergic Rhinitis In Adults And Children Over 12 Years Of Age.Ryaltris Relieves Symptoms Of Allergic Rhinitis, Including Stuffy Nose, Runny Nose, Nasal Itching, Sneezing, As Well As Itchy, Red And Watery Eyes.In Russia, Allergic Rhinitis Affects 10-20% Of The Population On Average, With Certain Regions Having A Higher Prevalence Rate Of 18-38%. Allergic Rhinitis Can Impact A Person'S Quality Of Life And Lead To Functional Impairments, As Well As Increase The Risk Of Having Asthma."Glenmark Has Built Strong Capabilities In The Area Of Respiratory Medicine And Is Among The Leading Players In This Therapy Area Across Several Markets Globally. Russia Is One Of The Key Markets For Us And We Are Consistently Looking To Expand Our Product Portfolio. We Are Delighted To Receive An Approval For Ryaltris Nasal Spray In The Russian Market. This New Innovative Addition To Our Portfolio Is Yet Another Major Step In Strengthening Glenmark'S Respiratory Focus In Russia And The Cis Region. Glenmark Has A Strong Established Presence In Russia For Over 30 Years, Which Will Enable Us To Lead The Commercialization Of This Product In The Country. We Look Forward To Being Able To Make This Innovative Product Available To Patients In Russia As Soon As Possible," Said Csaba Kantor, Senior Vice President - Russia &Amp; Cis Region, Glenmark Pharmaceuticals.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!